钙网蛋白突变在原发性血小板增多症与原发性骨髓纤维化中的实验室应用
本文为综述,探讨钙网蛋白(CALR)突变作为实验室生物标志物在原发性血小板增多症(ET)与原发性骨髓纤维化(PMF)中的临床应用。绝大多数致病性变异为第9外显子插入或缺失,导致C端序列改变并激活血小板生成素受体信号,促进巨核细胞增殖。综述强调其用于确认JAK2/MPL未突变病例的克隆性、区分克隆性骨髓增殖性疾病与反应性血小板增多,并主张在整合临床病理与分子检测的框架下使用。
要点
- CALR突变第9外显子插入/缺失可激活血小板生成素受体信号,促进巨核细胞增殖。
- 在JAK2/MPL未突变病例中,CALR检测有助于确认克隆性并与反应性血小板增多鉴别。
- CALR检测价值在整合骨髓形态、细胞遗传学、共突变与二代测序时最大,不宜单独使用。
核心结论
- CALR突变检测的临床信息在整合临床病理与分子检测背景下最大,而非作为单独检测使用。
- 需实现检测标准化、报告协调化,并对基于突变亚型与突变负荷的风险模型进行前瞻性验证。
研究设计与样本
- 综述,考察CALR突变作为实验室生物标志物在ET与PMF中的潜在临床效用。
主要发现
- 绝大多数致病性变异为第9外显子插入或缺失,产生突变C端序列并激活血小板生成素受体信号。
- CALR突变可用于确认JAK2/MPL未突变病例的克隆性,并区分克隆性骨髓增殖性疾病与反应性血小板增多。
关键数值与推荐
- 致病性变异绝大多数为第9外显子插入或缺失;其余数值原文未报告。
临床怎么用
- 在JAK2/MPL未突变的可疑ET/PMF病例中检测CALR以协助确认克隆性。
- 检测需关注检测方法选择、第9外显子罕见与非经典变异、分析灵敏度与分子报告。
- 判读应整合骨髓形态、细胞遗传学、共突变与二代测序结果。
局限性
- 检测方法选择、罕见与非经典变异识别、分析灵敏度与报告规范尚待标准化与协调。
- 基于突变亚型与突变负荷的风险模型尚需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutations in calreticulin have been identified as driver mutations in BCR-ABL1-negative myeloproliferative neoplasms (MPNs) and are especially important for diagnostics and prognosis in primary myelofibrosis and essential thrombocythemia. The vast majority of pathogenic variants are insertions or deletions in exon 9 that result in a mutant C-terminal sequence that activates the signaling of the thrombopoietin receptor, which in turn promotes megakaryocytic proliferation. This review examines the potential clinical utility of calreticulin mutations as laboratory biomarkers in essential thrombocythemia (ET) and primary myelofibrosis (PMF). It emphasizes their role in confirming clonality in JAK2/MPL-unmutated cases, distinguishing a clonal myeloproliferative disease from reactive thrombocytosis, clarifying the molecular interpretation, and guiding molecular diagnostic workflows. Special focus is placed on practical laboratory challenges, such as choosing assays, detecting rare and non-canonical variants in exon 9, analytical sensitivity, molecular reporting, and the integration of bone marrow morphology, cytogenetics, co-mutations, and next-generation sequencing. Overall, clinical information gained from calreticulin testing is greatest when it is used in an integrated clinicopathologic and molecular testing context rather than as a standalone test. To make calreticulin mutations more effectively used for diagnosis or prognosis in routine hematology practice, we need standardization of testing, harmonization of reporting, and prospective validation of risk-models based on both the subtypes and the burden of the mutation.
引用
- Bhat AA, Fuloria S, Thapa R, et al. Calreticulin mutations in essential thrombocythemia and primary myelofibrosis. Clin Chim Acta. 2026. PMID: 42225203. doi:10.1016/j.cca.2026.121129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。